All News
Insurance type, not race or distance to care, assoc'd w/ RA dz activity & burden. We need ^ rheums to care for socially deprived, rural, high comorbidity, Medicaid-covered RA pts w/ enhanced reimbursement & access to tx. Abs 0494 #ACR21 #RheumNow @RheumNow https://t.co/0es0i24gkS https://t.co/pBvhFR2DqE
Dr. Rachel Tate uptoTate ( View Tweet)
Biologics that can be use during pregnancy and lactation @rheumnow #acr21 reproductive guidelines https://t.co/4leM87GZI2
TheDaoIndex KDAO2011 ( View Tweet)
Delay breastfeeding within 4 hours if on pred> 20 mg. Meds safe in pregnancy and lactation #acr20 @RheumNow https://t.co/7l4jQw5idl
TheDaoIndex KDAO2011 ( View Tweet)
JAK inhibitors may be helpful for some patients with refractory adult and pediatric Still’s disease, but not in monotherapy (5 adults, 2 children, mean 11 month f/u, partial response in 4, failure in 3, steroid tapering difficult) @rheumnow #ACRbest #abst0195
Bella Mehta bella_mehta ( View Tweet)
Numeracy - (i.e. low health literacy) had lower self-reported adherence but paradoxically higher objective adherence in #Lupus @MithuRheum @rheumnow #ACRBest #abst0131
Bella Mehta bella_mehta ( View Tweet)
#ACR21 Abst#0463: Medicare claims data in ~3500 bDMARD-naive, sero+RA (avg 66 yo, 78%♀) showed those on Abatacept had longer time b4 tx stop (152d) @ 1yr vs TNFi (97d) or JAKi (89d)--is this reflective of tx efficacy? Where does ABT rank 4 u? @Rheumnow https://t.co/yfhxAsKBLl https://t.co/o84Ajmeyfk
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
No effect if ⤴️LDL in #Tocilizumab on #cardiovascular events vs other bDMARDs. Nice study from Corona. Ok why would we think that minor changes in lipids in RA & improved inflammation and ⤵️CRP would affect CV events? NNH is enormous & need yrs of f/u @RheumNow #ACR21 abst0268 https://t.co/cW65PmQ61u
Janet Pope Janetbirdope ( View Tweet)
Wonderful review on HES vs. EGPA by Dr. Amy Klion
⭐️1st line tx still steroids
⭐️New ACR 2021 EGPA guidelines
⭐️ANCA status can affect EGPA tx response
⭐️mepolizumab useful for EGPA and HES
⭐️ongoing trial for benralizumab (anti-IL-5R)
#ACR21
@RheumNow https://t.co/Xr99nAx5BA
Robert B Chao, MD doctorRBC ( View Tweet)
ACR and KL grades for identifying OA @carla_scanzello #ACR21 @RheumNow and New research proposed KOA criteria - updates in OA https://t.co/74j3RrpbG8
Bella Mehta bella_mehta ( View Tweet)
While angiographic change thankfully is uncommon in large vessel vasculitis patients
it's 3x more likely at a given site if there was been baseline PET/CT activity there.
Important step in understanding LVV natural history!
@KQuinnRheum @petercgrayson #ACR21 ABST0503 @RheumNow https://t.co/ROjLZyvEj4
David Liew drdavidliew ( View Tweet)
So you say LVV is a monophasic disease?
Look at these wavy lines, that keep on going up and down over time for both TAK and GCA - dynamic change.
The ESR/CRP might get better, but something below there keeps on burning...
@KQuinnRheum @petercgrayson #ACR21 ABST0504 @RheumNow https://t.co/sxTR16p6WJ
David Liew drdavidliew ( View Tweet)
#ACR21 Abst#0455
ABT improves subclin arthritis in +ACPA pts w/ MRI signs of [teno]synovitis or osteitis per ARIAA study
➡️61% w/ improved MRI findings vs 31% PBO
➡️Arthritis developed in 4 on ABT vs 17 PBO
Do you use ABT for early RA?
#ACRBest @Rheumnow https://t.co/btfH9lb6TU https://t.co/qOGkxSogZF
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
MAS in sJIA - retrospective multicenter study 147 pts- 2 peds clinics in Turkey.
22% developed MAS median 5 month
multiple attacks per pt - highest being 4
51% remined on the same biologic and resulted in improvement
@RheumNow #ACR21 #ACRBest #abst0246
Bella Mehta bella_mehta ( View Tweet)
Assisted reproductive tech for pts w/ rheum dz is safe for stable/quiescent dz #acr21 @ACRheum reproductive guideline @RheumNow https://t.co/312EuRSJrB
TheDaoIndex KDAO2011 ( View Tweet)
Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz duration 86 mos (7 Systemic, 1 Chr articular) w/ JAKi (Bari 4, Upa1, Tofa 2, Ruxo 2). There were no remissions, 50% had partial response @ 11 mos #ACR21 Abstr#0195 https://t.co/Ww8ONBrRqq
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR21 #pedsrheum
With so much work ahead, what to tackle first?
1⃣Gathering and organizing the top 10 priorities in cSLE https://t.co/H3ASXAfM4m
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Rheum Radiology Bootcamp
Rheum dz = increased risk of lung cancer
Important note: Fleischner recs for incidental nodules do not apply to immunosuppressed patients. Stay on alert for malignancy.
#ACR2021
Pedro Castillo _Castillo_Pedro ( View Tweet)
Consider baseline risk of lung cancer. Scleroderma and RA in particular at increased risk => lower threshold for getting initial CT. For incidental nodule, consider rescreening at 6-12 months, then space out.
#ACR2021
Pedro Castillo _Castillo_Pedro ( View Tweet)
Brepocitinib (TYK2/JAK1i) superior to PBO in PsA at week 16, w/ improvements in refractory domains continuing over 52 weeks. There were more AEs in the brepocitinib groups vs PBO over 16 weeks. Abs 0488 #ACR21 #RheumNow @RheumNow https://t.co/umk4REJwkS https://t.co/JYZVR3jyY5
Dr. Rachel Tate uptoTate ( View Tweet)